Article: Challenges in developing CAR T-cell therapies
Understand how quality control assays are being implemented in monitoring the development of CAR-T cells using high-throughput technologies in this article.
List view / Grid view
Understand how quality control assays are being implemented in monitoring the development of CAR-T cells using high-throughput technologies in this article.
The pipetting robot, flowbot® ONE, is available with a HEPA filter to make clean-up processes easy and effective, enabling you to keep your samples safe.
UCL researchers have developed a possible new treatment for neurological and psychiatric diseases, that works by reducing the excitability of overactive brain cells.
Discover how a plasmid DNA manufacturing platform process is helpful from preclinical studies to scaling production for late-stage and commercial needs.
Spanish researchers have discovered that vitamin C may hold the key to improving the efficacy of dendritic cell-derived anticancer therapies.
Researchers from the University of California have developed the first pre-clinical model of appendiceal cancer, containing all elements of the tumour.
Tune in to this podcast to hear experts discuss 3D cell models, organoids and the automation of complex cell assays.
Scientists have developed a new strategy to generate hair follicles in vitro with potential useful applications for treating hair loss, animal testing and drug screening.
An automated intracellular sensing system could provide an efficient approach to reveal the cellular characteristics of disease progression.
In a petri dish under an environmental condition reminiscent of ALS, the team found that the protein activates a unique pathway inside cells that increases survival and protects endothelial cells from toxic substances in the blood.
This whitepaper reviews the drug discovery progress for neurodegenerative diseases, focusing on promising candidates identified using iPSC technology.
Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.
Discover why the Hyperion+ Imaging System is the standard to assess tumour-immune interactions and get deep single-cell insights.
The pipetting robot, flowbot® ONE, is available with UV light to make clean-up processes easy and effective, enabling you to keep your samples safe.
Ensuring that drug candidates can reach the clinic is no easy task, so having models that can closely represent human pathology is crucial. Here, Dr Beth Hoffman, CEO of Origami Therapeutics, describes the successes and challenges of using human disease cell models in drug discovery.